|
44 Companies |
|
53 Products |
|
53 Products |
|
65 Mechanisms of Action |
|
1 Trial |
|
216 News |
|
| «12345» |
- | Inrebic (fedratinib) / BMS
Trial completion: Phase 2 Study of SAR302503 in Patients With Myelofibrosis (clinicaltrials.gov) - Jun 2, 2014
P2, N=30, Completed, Sponsor: Sanofi
Active, not recruiting --> Completed
- || Ojjaara (momelotinib) / GSK
Trial primary completion date, IO biomarker: Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (clinicaltrials.gov) - May 29, 2014
P1/2, N=61, Active, not recruiting, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Trial primary completion date: Dec 2013 --> Jun 2014
- Estybon (rigosertib) / Onconova, SymBio Pharma, Knight Therap
Trial primary completion date: Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL) (clinicaltrials.gov) - May 4, 2014
P1/2, N=34, Active, not recruiting, Sponsor: Onconova Therapeutics, Inc.
Trial primary completion date: Dec 2013 --> Jun 2014 Trial primary completion date: Aug 2013 --> Jan 2015
- Estybon (rigosertib) / Onconova, SymBio Pharma, Knight Therap
Trial completion date: Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL) (clinicaltrials.gov) - May 4, 2014
P1/2, N=34, Active, not recruiting, Sponsor: Onconova Therapeutics, Inc.
Trial primary completion date: Aug 2013 --> Jan 2015 Trial completion date: Jan 2014 --> Jun 2015
- prednisone / Generic mfg., lenalidomide / Generic mfg.
Trial completion date, Combination therapy: Lenalidomide and Prednisone in Treating Patients With Myelofibrosis (clinicaltrials.gov) - May 1, 2014
P2, N=48, Completed, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jan 2014 --> Jun 2015 Trial completion date: Mar 2012 --> Dec 2010
- | Jakafi (ruxolitinib) / Novartis, Incyte
Enrollment open: A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis (clinicaltrials.gov) - Apr 29, 2014
P3, N=50, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Mar 2012 --> Dec 2010 Not yet recruiting --> Recruiting
- | anagrelide CR (GALE-401) / SELLAS Life Sciences
New P2 trial: A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders (clinicaltrials.gov) - Apr 22, 2014
P2, N=20, Not yet recruiting, Sponsor: Galena Biopharma, Inc.
- Inrebic (fedratinib) / BMS
Enrollment change: Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly (clinicaltrials.gov) - Apr 6, 2014
P2, N=8, Completed, Sponsor: Sanofi
Not yet recruiting --> Recruiting N=20 --> 8
- Inrebic (fedratinib) / BMS
Trial completion: Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly (clinicaltrials.gov) - Apr 6, 2014
P2, N=8, Completed, Sponsor: Sanofi
N=20 --> 8 Active, not recruiting --> Completed
- |||||| Anathromb (anagrelide CR) / AOP Orphan Pharma
Enrollment open: TEAM-ET: Anagrelide Retard in Essential Thrombocythemia (clinicaltrials.gov) - Apr 1, 2014
P3, N=100, Recruiting, Sponsor: AOP Orphan Pharmaceuticals AG
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- imetelstat (GRN163L) / Geron
Trial suspension: Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera (clinicaltrials.gov) - Mar 23, 2014
P2, N=40, Suspended, Sponsor: Geron Corporation
Not yet recruiting --> Recruiting Active, not recruiting --> Suspended
- ||| Jakafi (ruxolitinib) / Novartis, Incyte
New P3 trial: A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis (clinicaltrials.gov) - Mar 12, 2014
P3, N=50, Recruiting, Sponsor: Novartis Pharmaceuticals
- | daunorubicin / Generic mfg., cyclophosphamide / Generic mfg., decitabine / Generic mfg.
New P2 trial: Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms (clinicaltrials.gov) - Mar 10, 2014
P2, N=450, Recruiting, Sponsor: Hospital Israelita Albert Einstein
- |||||||||| Anathromb (anagrelide CR) / AOP Orphan Pharma
New P3 trial: TEAM-ET: Anagrelide Retard in Essential Thrombocythemia (clinicaltrials.gov) - Mar 2, 2014
P3, N=100, Recruiting, Sponsor: AOP Orphan Pharmaceuticals AG
- | Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial completion: Combination Chemotherapy and Antithymocyte Globulin in Reducing Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplantation For Myelodysplastic Syndrome or Myeloproliferative Disorder (clinicaltrials.gov) - Feb 22, 2014
P1/2, N=0, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Suspended Active, not recruiting --> Completed
- | Istodax (romidepsin) / Astellas, BMS
Trial completion: Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders (clinicaltrials.gov) - Feb 22, 2014
P1, N=36, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Suspended --> Completed
- Fodosine (forodesine) / Mundipharma, BioCryst
Trial completion: BCX-1777 in Treating Patients With Refractory Cancer (clinicaltrials.gov) - Feb 22, 2014
P1, N=0, Completed, Sponsor: BioCryst Pharmaceuticals
Suspended --> Completed Active, not recruiting --> Completed
- | peripheral blood stem cell transplantation / National Cancer Institute
Trial completion: Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Myeloproliferative Disorder (clinicaltrials.gov) - Feb 22, 2014
P1/2, N=30, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed Recruiting --> Completed
- | imatinib / Generic mfg.
Trial completion, Metastases: Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction (clinicaltrials.gov) - Feb 22, 2014
P1, N=60, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed No longer recruiting --> Completed
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen, peripheral blood stem cell transplantation / National Cancer Institute
Trial completion: Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Myelofibrosis (clinicaltrials.gov) - Feb 19, 2014
P2, N=0, Completed, Sponsor: Fred Hutchinson Cancer Research Center
No longer recruiting --> Completed Active, not recruiting --> Completed
- | peripheral blood stem cell transplantation / National Cancer Institute
Trial completion: Combination Chemotherapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloproliferative Disorders (clinicaltrials.gov) - Feb 19, 2014
P2, N=20, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon (clinicaltrials.gov) - Feb 19, 2014
P1/2, N=0, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | amphotericin b liposome / Generic mfg.
Trial completion: Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment (clinicaltrials.gov) - Feb 19, 2014
P3, N=0, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Zarnestra (tipifarnib) / Kura Oncology
Trial completion, Metastases: Tipifarnib in Treating Patients With Advanced Hematologic Cancer (clinicaltrials.gov) - Feb 19, 2014
P1, N=36, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Suspended --> Completed
- | cyclophosphamide / Generic mfg.
Trial completion: Bone Marrow Transplantation in Treating Patients With Hematologic Cancer (clinicaltrials.gov) - Feb 19, 2014
P2, N=0, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Suspended --> Completed Active, not recruiting --> Completed
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen, peripheral blood stem cell transplantation / National Cancer Institute
Trial completion, Post-transplantation: Stem Cell Transplantation in Treating Patients With Hematologic Cancer (clinicaltrials.gov) - Feb 19, 2014
P1, N=0, Completed, Sponsor: Northwestern University
Active, not recruiting --> Completed Not yet recruiting --> Completed
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen, peripheral blood stem cell transplantation / National Cancer Institute
Trial completion: Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer (clinicaltrials.gov) - Feb 19, 2014
P1, N=0, Completed, Sponsor: Northwestern University
Not yet recruiting --> Completed Not yet recruiting --> Completed
- | topotecan / Generic mfg., 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Trial completion, Combination therapy, Metastases: Combination Chemotherapy in Treating Patients With Advanced Cancer (clinicaltrials.gov) - Feb 19, 2014
P1, N=30, Completed, Sponsor: New York University School of Medicine
Not yet recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion, Metastases: Monoclonal Antibody Therapy in Treating Patients With Advanced Cancer (clinicaltrials.gov) - Feb 19, 2014
P1, N=27, Completed, Sponsor: University of Arizona
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | decitabine / Generic mfg.
Trial completion, Metastases: Decitabine in Treating Patients With Melanoma or Other Advanced Cancer (clinicaltrials.gov) - Feb 19, 2014
P1, N=0, Completed, Sponsor: California Cancer Consortium
Active, not recruiting --> Completed Not yet recruiting --> Completed
- | Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap
Trial completion, Metastases: Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer (clinicaltrials.gov) - Feb 19, 2014
P2, N=0, Completed, Sponsor: Hoag Memorial Hospital Presbyterian
Not yet recruiting --> Completed Active, not recruiting --> Completed
- || AZD1480 / AstraZeneca
Enrollment change, Tumor mutational burden: Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases (clinicaltrials.gov) - Feb 17, 2014
P1, N=65, Active, not recruiting, Sponsor: AstraZeneca
Active, not recruiting --> Completed N=35 --> 65
- | Jakafi (ruxolitinib) / Novartis, Incyte
P2 data, Enrollment change: Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF) (clinicaltrials.gov) - Jan 11, 2014
P4, N=48, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
N=35 --> 65 N=33 --> 48
- | Jakafi (ruxolitinib) / Novartis, Incyte
Enrollment closed, P2 data: Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF) (clinicaltrials.gov) - Jan 11, 2014
P4, N=48, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
N=33 --> 48 Recruiting --> Active, not recruiting
- Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe, Cytovene (ganciclovir) / Roche
Enrollment change: Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant (clinicaltrials.gov) - Jan 1, 2014
P=N/A, N=153, Completed, Sponsor: City of Hope Medical Center
Recruiting --> Active, not recruiting N=300 --> 153
- Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe, Cytovene (ganciclovir) / Roche
Trial completion: Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant (clinicaltrials.gov) - Jan 1, 2014
P=N/A, N=153, Completed, Sponsor: City of Hope Medical Center
N=300 --> 153 Suspended --> Completed
- fludarabine IV / Generic mfg., mycophenolate mofetil / Generic mfg.
Enrollment open, Combination therapy, IO biomarker, Post-transplantation: Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer (clinicaltrials.gov) - Dec 19, 2013
P1, N=20, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Suspended --> Completed Active, not recruiting --> Recruiting
- ||| Inrebic (fedratinib) / BMS
Enrollment closed: Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia (clinicaltrials.gov) - Dec 16, 2013
P2, N=90, Active, not recruiting, Sponsor: Sanofi
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||| Inrebic (fedratinib) / BMS, Jakafi (ruxolitinib) / Incyte
Enrollment closed: JAKARTA2: Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib (clinicaltrials.gov) - Sep 29, 2013
P2, N=70, Active, not recruiting, Sponsor: Sanofi
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Sutent (sunitinib) / Pfizer
Trial completion: Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy (clinicaltrials.gov) - Sep 26, 2013
P1, N=42, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- prednisone / Generic mfg., lenalidomide / Generic mfg.
Trial completion, Combination therapy: Lenalidomide and Prednisone in Treating Patients With Myelofibrosis (clinicaltrials.gov) - Jul 22, 2013
P2, N=48, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap
Trial completion, Metastases: Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation (clinicaltrials.gov) - Jul 2, 2013
P1/2, N=37, Completed, Sponsor: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Active, not recruiting --> Completed Active, not recruiting --> Completed
- cyclophosphamide / Generic mfg., busulfan / Generic mfg.
Trial completion: Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome (clinicaltrials.gov) - Jul 1, 2013
P=N/A, N=52, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Enrollment change, HEOR: Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer (clinicaltrials.gov) - Jun 25, 2013
P=N/A, N=80, Active, not recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
Active, not recruiting --> Completed N=64 --> 80
- Trial withdrawal: Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer (clinicaltrials.gov) - Jun 16, 2013
P1/2, N=0, Withdrawn, Sponsor: University of Nebraska
N=64 --> 80 Terminated --> Withdrawn
- Enrollment change: Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer (clinicaltrials.gov) - Jun 16, 2013
P1/2, N=0, Withdrawn, Sponsor: University of Nebraska
Terminated --> Withdrawn N=20 --> 0
- Zarnestra (tipifarnib) / Kura Oncology
Trial completion: Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasia (clinicaltrials.gov) - Jun 2, 2013
P2, N=35, Completed, Sponsor: National Cancer Institute (NCI)
N=20 --> 0 Active, not recruiting --> Completed
- | Jakafi (ruxolitinib) / Novartis, Incyte
Trial completion: Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis (clinicaltrials.gov) - May 12, 2013
P2, N=45, Completed, Sponsor: Incyte Corporation
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Jakafi (ruxolitinib) / Novartis, Incyte
Trial initiation date: Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis (clinicaltrials.gov) - Apr 25, 2013
P2, N=28, Recruiting, Sponsor: Mayo Clinic
Active, not recruiting --> Completed Initiation date: Dec 2012 --> Apr 2013
- | Jakafi (ruxolitinib) / Novartis, Incyte
Enrollment open: Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis (clinicaltrials.gov) - Apr 25, 2013
P2, N=28, Recruiting, Sponsor: Mayo Clinic
Initiation date: Dec 2012 --> Apr 2013 Not yet recruiting --> Recruiting